Table 3. Case description and sphere formation and tumorigenic activity of CD44+ and CD54+ gastric cancer cells in circulation.
| Case | Sex/age | Grade | Stage | Metastasis | Chemotherapy/cycles | Surgery | CD44+CD54+ expression (%)1 | Sphere formation | Tumor formation2 |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M/57 | Poor | TXNXM1 | Liver | Lapatinib (1) | No | 5.1 | Yes | 9 × 103 (3/3) |
| 2 | M/74 | Poor with signet-ring cell | T2N1M0 | No | FOLFOX (3) | Yes | 0.7 | Yes | 9 × 103 (3/3) |
| 3 | M/61 | Poor | TXNXM0 | No | FOLFOX (1) | Yes | 0.9 | Yes | 9 × 103 (3/3) |
| 4 | M/59 | Poor | T2N2M1 | Bone | DCF (2) | Yes | 2.1 | Yes | 9 × 103 (3/3) |
| 5 | M/66 | Poor | TXNXM1 | Liver | Mfolfox7 (4) | Yes | 0.9 | Yes | 9 × 103 (3/3) |
| 6 | M/59 | Poor with signet-ring cell | T2N1MO | No | FOLFOX (2) | Yes | 0.5 | No | No |
| 7 | M/62 | Poor with signet-ring cell | T2N1M0 | No | FOLFOX (2) | Yes | 0.4 | Yes | 9 × 103 (3/3) |
1Ratio of CD44 and CD54 double-positive cells is derived from non-hematopoietic and non-endothelial cells in the peripheral blood of patients. Non-hematopoietic and non-endothelial cells were obtained by first depleting hematopoietic and endothelial cells by specific antibodies before FACS analysis and gating out the hematopoietic and endothelial-specific antibody labeling during FACS analysis.
2Number of CD44+CD54+ cells from spheres injected into mice (number of mice which have tumor formation in three mice).